↓ Skip to main content

Epidemiology of Antituberculosis Drug Resistance in Saudi Arabia: Findings of the First National Survey

Overview of attention for article published in Antimicrobial Agents and Chemotherapy, March 2013
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (73rd percentile)
  • Good Attention Score compared to outputs of the same age and source (70th percentile)

Mentioned by

twitter
7 X users
facebook
1 Facebook page

Citations

dimensions_citation
44 Dimensions

Readers on

mendeley
116 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Epidemiology of Antituberculosis Drug Resistance in Saudi Arabia: Findings of the First National Survey
Published in
Antimicrobial Agents and Chemotherapy, March 2013
DOI 10.1128/aac.02403-12
Pubmed ID
Authors

Sahal Al-Hajoj, Bright Varghese, Mohammed M. Shoukri, Ruba Al-Omari, Mais Al-Herbwai, Fahad AlRabiah, Abdulrahman A. Alrajhi, Naila Abuljadayel, Sahar Al-Thawadi, Alimuddin Zumla, Matteo Zignol, Mario C. Raviglione, Ziad Memish

Abstract

The real magnitude of antituberculosis (anti-TB) drug resistance in Saudi Arabia is still unknown because the available data are based on retrospective laboratory studies that were limited to hospitals or cities. A representative national survey was therefore conducted to investigate the levels and patterns of anti-TB drug resistance and explore risk factors. Between August 2009 and July 2010, all culture-positive TB patients diagnosed in any of the tuberculosis reference laboratories of the country were enrolled. Isolates obtained from each patient were tested for susceptibility to first-line anti-TB drugs by the automated Bactec MGIT 960 method. Of the 2,235 patients enrolled, 75 cases (3.4%) were lost due to culture contamination and 256 (11.5%) yielded nontuberculous mycobacteria (NTM). Finally, 1,904 patients (85.2% of those enrolled) had available drug susceptibility testing results. Monoresistance to streptomycin (8.1%; 95% confidence interval [CI], 7.2 to 9.1), isoniazid (5.4%; 95% CI, 4.7 to 6.2), rifampin (1%; 95% CI, 0.7 to 1.3) and ethambutol (0.8%; 95% CI, 0.5 to 1.2) were observed. Multidrug-resistant TB (MDR-TB) was found in 1.8% (95% CI, 1.4 to 2.4) and 15.9% (95% CI, 15.4 to 16.5) of new and previously treated TB cases, respectively. A treatment history of active TB, being foreign-born, having pulmonary TB, and living in the Western part of the country were the strongest independent predictors of MDR-TB. Results from the first representative national anti-TB drug resistance survey in Saudi Arabia suggest that the proportion of MDR-TB is relatively low, though there is a higher primary drug resistance. A strengthened continuous surveillance system to monitor trends over time and second-line anti-TB drug resistance as well as implementation of innovative control measures, particularly among immigrants, is warranted.

X Demographics

X Demographics

The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 116 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
India 1 <1%
Unknown 115 99%

Demographic breakdown

Readers by professional status Count As %
Researcher 19 16%
Student > Master 14 12%
Student > Bachelor 13 11%
Other 12 10%
Student > Postgraduate 12 10%
Other 23 20%
Unknown 23 20%
Readers by discipline Count As %
Medicine and Dentistry 45 39%
Pharmacology, Toxicology and Pharmaceutical Science 10 9%
Immunology and Microbiology 9 8%
Biochemistry, Genetics and Molecular Biology 8 7%
Agricultural and Biological Sciences 5 4%
Other 12 10%
Unknown 27 23%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 November 2016.
All research outputs
#6,963,672
of 25,374,647 outputs
Outputs from Antimicrobial Agents and Chemotherapy
#6,504
of 15,579 outputs
Outputs of similar age
#55,412
of 207,610 outputs
Outputs of similar age from Antimicrobial Agents and Chemotherapy
#38
of 128 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 15,579 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one has gotten more attention than average, scoring higher than 58% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 207,610 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 128 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.